

Dear collaborators, partners, and members of the MoLBi community,

June has been another productive month for the Monash Live-Biobanking (MoLBi) platform, marked by continued growth, exciting new collaborations, and important progress towards translating our research into clinical impact.

This month, the brain cancer community was saddened by the passing of Professor Richard Scolyer. Professor Scolyer's extraordinary contributions to melanoma and brain cancer research have inspired clinicians and scientists around the world. His courage throughout his own battle with brain cancer serves as a powerful reminder of why we do what we do. His legacy strengthens our resolve to work harder and to accelerate the translation of research discoveries into meaningful treatments for patients with brain cancer.

MoLBi has now reached **315 enrolled participants**, representing another important milestone for the platform. This continued growth reflects the outstanding support of our neurosurgical, pathology, theatre, research and consumer teams who make real-time tumour collection possible. As our clinical network continues to expand, so too does our opportunity to generate clinically meaningful datasets and develop new precision medicine approaches for patients across Victoria. During the month, we also commenced a new collaboration with engineering colleagues at RMIT University to submit a Cancer Council Victoria Grant-in-Aid application exploring novel technologies for targeted drug delivery directly into brain tissue.

One of the highlights of June was the opportunity for Justin Moore and I to present the MoLBi journey and our end-to-end vision for personalised TCR-T cell therapy at **the Brain Tumour Research Group** seminar on 18 June. It was encouraging to share our platform with leading brain cancer researchers from across Australia and to discuss how living patient-derived tumour models can accelerate antigen discovery, therapeutic development, and ultimately personalised cellular therapies. The enthusiastic discussion following the presentation reinforced the growing interest in integrated translational platforms capable of taking discoveries from the operating theatre to personalised therapies.



Our Phase Zero investigator-initiated trial platform also reached an important milestone this month. Following a constructive meeting with the Monash Health Human Research Ethics Committee, we now have a clear pathway forward towards approval. We are particularly grateful to our consumer advocates, whose thoughtful contributions during the meeting reinforced the importance of maintaining a patient-centred approach as we develop these pioneering brain tumour translational studies.

Strengthening multidisciplinary collaboration continues to be a major focus for MoLBi. This month, our team visited the [Melbourne Centre for Nanofabrication](#), hosted by Professor



Nicolas Voelcker, Head of the Victorian Node. We were also pleased to be joined by Professor Raman Singh (Department of Engineering) and Associate Professor Santosh Panjekar (ANSTO). The visit provided an excellent opportunity to explore world-class nanofabrication facilities, including Class 10,000 and Class 100 cleanrooms, advanced microscopy suites, reconfigurable biochemistry laboratories, and PC2

facilities. More importantly, it strengthened our growing engineering–nanofabrication–medicine partnership as we work together to develop innovative implantable technologies and precision therapeutic platforms for brain cancer.

Finally, we would like to congratulate some of our wonderful consumer advocates, the Dalton family, for another year of the [Baking for Brain Cancer initiative](#) they started in 2025. Alongside 92 other bakeries and cafes across Australia, Baking for Brain Cancer raised more than **\$135,000** in 2026, representing over a quarter of a million dollars raised in the first two years of the initiative.



Thank you, as always, to our clinicians, researchers, students, consumers, and collaborators for your continued enthusiasm and support. Every tumour collected, every collaboration established, and every project advanced brings us one step closer to delivering better outcomes for patients.

With best wishes,



Dr Gwo Yaw Ho
Founder and Chair, Monash Live-Biobanking



Professor Justin Moore
Director of Neurosurgery, Monash Health